UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT
OF 1934
For the quarterly period ended March 31, 2003
Commission File Number 1-14798
IVAX DIAGNOSTICS, INC.
(Exact name of registrant as specified in its charter)
| Delaware (State or other jurisdiction of incorporation or organization) |
11-3500746 (I.R.S. Employer Identification No.) |
| 2140 North Miami Avenue, Miami, Florida (Address of principal executive offices) |
33127 (Zip Code) |
(305) 324-2300
(Registrants telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o
Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act). Yes o No x
Indicate the number of shares outstanding of each of the issuers classes of common stock, as of the latest practicable date.
27,534,079 shares of Common Stock, $ .01 par value, outstanding as of May 6, 2003.
IVAX DIAGNOSTICS, INC.
INDEX
|
|
|
|
|
|
PAGE NO. |
|
|
|
|
|
|
|
| PART I |
|
FINANCIAL INFORMATION |
| ||
|
|
|
|
|
|
|
|
|
|
Item 1 |
|
Financial Statements |
|
|
|
|
|
|
|
|
|
|
|
|
|
Consolidated Balance Sheets as of March 31, 2003 and December 31, 2002 |
2 |
|
|
|
|
|
|
|
|
|
|
|
|
Consolidated Statements of Operations for the three months ended March 31, 2003 and 2002 |
3 |
|
|
|
|
|
|
|
|
|
|
|
|
Consolidated Statements of Cash Flows for the three months ended March 31, 2003 and 2002 |
4 |
|
|
|
|
|
|
|
|
|
|
|
|
5 | |
|
|
|
|
|
|
|
|
|
|
Item 2 |
|
Managements Discussion and Analysis of Financial Condition and Results of Operations |
11 |
|
|
|
|
|
|
|
|
|
|
Item 3 |
|
19 | |
|
|
|
|
|
|
|
|
|
|
Item 4 |
|
20 | |
|
|
|
|
|
|
|
| PART II |
|
OTHER INFORMATION |
| ||
|
|
|
|
|
|
|
|
|
|
Item 1 |
|
21 | |
|
|
|
|
|
|
|
|
|
|
Item 6 |
|
22 | |
PART I - FINANCIAL INFORMATION
Item 1 - Financial Statements
IVAX DIAGNOSTICS, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
|
|
|
March 31, |
|
December 31, |
| ||
|
|
|
|
|
|
| ||
|
|
|
(Unaudited) |
|
|
| ||
|
|
|
|
|
|
|
|
|
| ASSETS |
|
|
|
|
|
|
|
| Current assets: |
|
|
|
|
|
|
|
| Cash and cash equivalents |
|
$ |
16,389,167 |
|
$ |
15,941,663 |
|
| Accounts receivable, net of allowances for doubtful accounts of $2,553,516 in 2003 and $2,392,553 in 2002 |
|
|
6,354,435 |
|
|
5,721,400 |
|
| Inventories |
|
|
3,999,962 |
|
|
4,246,893 |
|
| Other current assets |
|
|
1,356,972 |
|
|
1,267,827 |
|
|
|
|
|
|
|
|
|
|
| Total current assets |
|
|
28,100,536 |
|
|
27,177,783 |
|
| Property, plant and equipment, net |
|
|
1,959,971 |
|
|
1,995,997 |
|
| Goodwill, net |
|
|
6,771,883 |
|
|
6,794,147 |
|
| Equipment on lease |
|
|
1,156,870 |
|
|
1,189,456 |
|
| Other assets |
|
|
272,769 |
|
|
265,321 |
|
|
|
|
|
|
|
|
|
|
| Total assets |
|
$ |
38,262,029 |
|
$ |
37,422,704 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| LIABILITIES AND SHAREHOLDERS EQUITY |
|
|
|
|
|
|
|
| Current liabilities: |
|
|
|
|
|
|
|
| Accounts payable |
|
$ |
829,815 |
|
$ |
881,657 |
|
| Accrued expenses and other current liabilities |
|
|
3,543,740 |
|
|
2,775,110 |
|
|
|
|
|
|
|
|
|
|
| Total current liabilities |
|
|
4,373,555 |
|
|
3,656,767 |
|
|
|
|
|
|
|
|
|
|
| Other long-term liabilities |
|
|
402,004 |
|
|
370,405 |
|
|
|
|
|
|
|
|
|
|
| Commitments and contingencies |
|
|
|
|
|
|
|
| Shareholders equity: |
|
|
|
|
|
|
|
| Common stock, $0.01 par value, authorized 50,000,000 shares,issued and outstanding 27,519,079 in 2003 and 2002 |
|
|
275,190 |
|
|
275,190 |
|
| Capital in excess of par value |
|
|
43,244,204 |
|
|
43,095,554 |
|
| Accumulated deficit |
|
|
(8,713,769 |
) |
|
(8,426,409 |
) |
| Accumulated other comprehensive loss |
|
|
(1,319,155 |
) |
|
(1,548,803 |
) |
|
|
|
|
|
|
|
|
|
| Total shareholders equity |
|
|
33,486,470 |
|
|
33,395,532 |
|
|
|
|
|
|
|
|
|
|
| Total liabilities and shareholders equity |
|
$ |
38,262,029 |
|
$ |
37,422,704 |
|
|
|
|
|
|
|
|
|
|
The accompanying Notes to Consolidated Financial Statements are an integral part of these balance sheets.
2
IVAX DIAGNOSTICS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
| Three Months Ended March 31, |
|
2003 |
|
2002 |
| ||
|
|
|
|
|
|
| ||
| Net revenues |
|
$ |
4,443,568 |
|
$ |
2,506,288 |
|
| Cost of sales |
|
|
2,011,129 |
|
|
1,249,445 |
|
|
|
|
|
|
|
|
|
|
| Gross profit |
|
|
2,432,439 |
|
|
1,256,843 |
|
|
|
|
|
|
|
|
|
|
| Operating expenses: |
|
|
|
|
|
|
|
| Selling |
|
|
1,285,228 |
|
|
794,093 |
|
| General and administrative |
|
|
1,164,445 |
|
|
936,933 |
|
| Research and development |
|
|
346,726 |
|
|
358,495 |
|
|
|
|
|
|
|
|
|
|
| Total operating expenses |
|
|
2,796,399 |
|
|
2,089,521 |
|
|
|
|
|
|
|
|
|
|
| Loss from operations |
|
|
(363,960 |
) |
|
(832,678 |
) |
|
|
|
|
|
|
|
|
|
| Other income: |
|
|
|
|
|
|
|
| Interest income |
|
|
51,207 |
|
|
166,806 |
|
| Other income (expense), net |
|
|
38,811 |
|
|
(15,078 |
) |
|
|
|
|
|
|
|
|
|
| Total other income, net |
|
|
90,018 |
|
|
151,728 |
|
|
|
|
|
|
|
|
|
|
| Loss from continuing operations before income taxes |
|
|
(273,942 |
) |
|
(680,950 |
) |
| Provision for income taxes |
|
|
13,418 |
|
|
33,322 |
|
|
|
|
|
|
|
|
|
|
| Net loss |
|
$ |
(287,360 |
) |
$ |
(714,272 |
) |
|
|
|
|
|
|
|
|
|
| Basic and diluted loss per common share |
|
$ |
(.01 |
) |
$ |
(.02 |
) |
|
|
|
|
|
|
|
|
|
| WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING: |
|
|
|
|
|
|
|
| Basic and diluted |
|
|
27,519,079 |
|
|
28,635,652 |
|
|
|
|
|
|
|
|
|
|
The accompanying Notes to Consolidated Financial Statements are an integral part of these statements.
3
IVAX DIAGNOSTICS AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
| Three Months Ended March 31, |
|
2003 |
|
2002 |
| ||
|
|
|
|
|
|
| ||
| Cash flows from operating activities: |
|
|
|
|
|
|
|
| Net loss |
|
$ |
(287,360 |
) |
$ |
(714,272 |
) |
| Adjustments to reconcile net loss to net cash flows provided by (used in) operating activities: |
|
|
|
|
|
|
|
| Depreciation and amortization |
|
|
287,024 |
|
|
186,374 |
|
| Provision for losses on accounts receivable |
|
|
71,985 |
|
|
29,691 |
|
| Stock option compensation expense |
|
|
148,650 |
|
|
148,650 |
|
| Changes in operating assets and liabilities: |
|
|
|
|
|
|
|
| Accounts receivable |
|
|
(545,655 |
) |
|
(359,986 |
) |
| Inventories |
|
|
305,835 |
|
|
158,887 |
|
| Other current assets |
|
|
(41,210 |
) |
|
70,338 |
|
| Other assets |
|
|
158 |
|
|
1,051 |
|
| Accounts payable and accrued expenses |
|
|
652,775 |
|
|
(68,338 |
) |
| Other long-term liabilities |
|
|
16,390 |
|
|
7,749 |
|
|
|
|
|
|
|
|
|
|
| Net cash flows provided by (used in) operating activities |
|
|
608,592 |
|
|
(539,856 |
) |
|
|
|
|
|
|
|
|
|
| Cash flows from investing activities: |
|
|
|
|
|
|
|
| Capital expenditures |
|
|
(34,530 |
) |
|
(23,389 |
) |
| Acquisitions of marketable securities |
|
|
|
|
|
(2,050,000 |
) |
| Acquisitions of equipment on lease |
|
|
(157,488 |
) |
|
(179,006 |
) |
|
|
|
|
|
|
|
|
|
| Net cash flows used in investing activities |
|
|
(192,018 |
) |
|
(2,252,395 |
) |
|
|
|
|
|
|
|
|
|
| Cash flows from financing activities: |
|
|
|
|
|
|
|
| Change in balance due to IVAX Corporation |
|
|
|
|
|
82,000 |
|
|
|
|
|
|
|
|
|
|
| Net cash flows provided by financing activities |
|
|
|
|
|
82,000 |
|
|
|
|
|
|
|
|
|
|
| Effect of exchange rate changes on cash and cash equivalents |
|
|
30,930 |
|
|
(32,959 |
) |
|
|
|
|
|
|
|
|
|
| Net increase (decrease) in cash and cash equivalents |
|
|
447,504 |
|
|
(2,743,210 |
) |
| Cash and cash equivalents at the beginning of the year |
|
|
15,941,663 |
|
|
23,282,155 |
|
|
|
|
|
|
|
|
|
|
| Cash and cash equivalents at the end of the period |
|
$ |
16,389,167 |
|
$ |
20,538,945 |
|
|
|
|
|
|
|
|
|
|
| Supplemental disclosures: |
|
|
|
|
|
|
|
| Interest paid |
|
$ |
|
|
$ |
|
|
|
|
|
|
|
|
|
|
|
| Income tax payments (refunds) |
|
$ |
|
|
$ |
|
|
|
|
|
|
|
|
|
|
|
The accompanying Notes to Consolidated Financial Statements are an integral part of these statements.